Differences in SARS-CoV-2 Specific Humoral and Cellular Immune Responses After Contralateral and Ipsilateral COVID-19 Vaccination

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2023 Aug 13

PMID 37574375

Authors

Laura Ziegler

Verena Klemis

Tina Schmidt

Sophie Schneitler

Christina Baum

Jurgen Neumann

Soren L Becker

Barbara C Gartner

Urban Sester

Martina Sester

Affiliations

Soon will be listed here.

Abstract

Background: Individual doses of dual-dose vaccine-regimens are sequentially administered into the deltoid muscle, but little attention has so far been paid to the immunological effects of choosing the ipsilateral or the contralateral side for the second dose.

Methods: In an observational study, 303 previously naive individuals were recruited, who received the second dose of the COVID-19 vaccine BNT162b2 on either the ipsilateral (n = 147) or the contralateral side (n = 156). Spike-specific IgG, IgG-avidity, and neutralizing antibodies were quantified using ELISA and a surrogate assay 2 weeks after dose 2. A subgroup of 143 individuals (64 ipsilateral, 79 contralateral) was analysed for spike-specific CD4 and CD8 T-cells using flow-cytometry.

Findings: Median spike-specific IgG-levels did not differ after ipsilateral (4590 (IQR 3438) BAU/ml) or contralateral vaccination (4002 (IQR 3524) BAU/ml, p = 0.106). IgG-avidity was also similar (p = 0.056). However, neutralizing activity was significantly lower after contralateral vaccination (p = 0.024). Likewise, median spike-specific CD8 T-cell levels were significantly lower (p = 0.004). Consequently, the percentage of individuals with detectable CD8 T-cells was significantly lower after contralateral than after ipsilateral vaccination (43.0% versus 67.2%, p = 0.004). Spike specific CD4 T-cell levels were similar in both groups, but showed significantly higher CTLA-4 expression after contralateral vaccination (p = 0.011). These effects were vaccine-specific, as polyclonally stimulated T-cell levels did not differ.

Interpretation: Both ipsilateral and contralateral vaccination induce a strong immune response, but secondary boosting is more pronounced when choosing vaccine administration-routes that allows for drainage by the same lymph nodes used for priming. Higher neutralizing antibody activity and higher levels of spike-specific CD8 T-cells may have implications for protection from infection and severe disease and support general preference for ipsilateral vaccination.

Funding: Financial support was provided in part by the State chancellery of the Saarland to M.S.

Citing Articles

Viral Infection and Dissemination Through the Lymphatic System.

Brisse M, Hickman H Microorganisms. 2025; 13(2).

PMID: 40005808 PMC: 11858409. DOI: 10.3390/microorganisms13020443.

Insights into pathologic mechanisms occurring during serious adverse events following live zoster vaccination.

Kennedy P, Grose C J Virol. 2025; 99(2):e0181624.

PMID: 39818965 PMC: 11852805. DOI: 10.1128/jvi.01816-24.

Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.

Ying B, Liang C, Desai P, Scheaffer S, Elbashir S, Edwards D J Virol. 2024; 98(9):e0057424.

PMID: 39194250 PMC: 11406931. DOI: 10.1128/jvi.00574-24.

Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses.

Pattinson D, Jester P, Gu C, Guan L, Armbrust T, Petrie J EBioMedicine. 2024; 103:105103.

PMID: 38574407 PMC: 11004685. DOI: 10.1016/j.ebiom.2024.105103.

Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity.

Abbasi S, Matsui-Masai M, Yasui F, Hayashi A, Tockary T, Mochida Y Mol Ther. 2024; 32(5):1266-1283.

PMID: 38569556 PMC: 11081875. DOI: 10.1016/j.ymthe.2024.03.022.

References

Ayati N, Evans S, Zakavi S, Gruenewald S . Comparison between viral vector and mRNA based COVID-19 vaccination in prevalence and severity of regional immune reactions, and F-FDG PET/CT features. Asia Ocean J Nucl Med Biol. 2023; 11(1):4-12. PMC: 9803623. DOI: 10.22038/AOJNMB.2022.63110.1443. View

Iro M, Khatami A, Marshall A, Pace D, Voysey M, McKenna J . Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled.... Lancet Infect Dis. 2015; 15(2):172-80. DOI: 10.1016/S1473-3099(14)71057-6. View

Schub D, Klemis V, Schneitler S, Mihm J, Lepper P, Wilkens H . High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19. JCI Insight. 2020; 5(20). PMC: 7605520. DOI: 10.1172/jci.insight.142167. View

Turner J, OHalloran J, Kalaidina E, Kim W, Schmitz A, Zhou J . SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021; 596(7870):109-113. PMC: 8935394. DOI: 10.1038/s41586-021-03738-2. View

Lederer K, Bettini E, Parvathaneni K, Painter M, Agarwal D, Lundgreen K . Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell. 2022; 185(6):1008-1024.e15. PMC: 8808747. DOI: 10.1016/j.cell.2022.01.027. View

Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S . Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021; 27(9):1530-1535. PMC: 8440177. DOI: 10.1038/s41591-021-01464-w. View

Kedl R, Lindsay R, Finlon J, Lucas E, Friedman R, Tamburini B . Migratory dendritic cells acquire and present lymphatic endothelial cell-archived antigens during lymph node contraction. Nat Commun. 2017; 8(1):2034. PMC: 5725486. DOI: 10.1038/s41467-017-02247-z. View

Debes A, Xiao S, Colantuoni E, Egbert E, Caturegli P, Gadala A . Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers. JAMA Intern Med. 2021; 181(12):1660-1662. PMC: 8369424. DOI: 10.1001/jamainternmed.2021.4580. View

Kim W, Zhou J, Horvath S, Schmitz A, Sturtz A, Lei T . Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature. 2022; 604(7904):141-145. PMC: 9204750. DOI: 10.1038/s41586-022-04527-1. View

10.

Hermann E, Lee B, Balte P, Xanthakis V, Kirkpatrick B, Cushman M . Association of Symptoms After COVID-19 Vaccination With Anti-SARS-CoV-2 Antibody Response in the Framingham Heart Study. JAMA Netw Open. 2022; 5(10):e2237908. PMC: 9587476. DOI: 10.1001/jamanetworkopen.2022.37908. View

11.

Kuraoka M, Yeh C, Bajic G, Kotaki R, Song S, Windsor I . Recall of B cell memory depends on relative locations of prime and boost immunization. Sci Immunol. 2022; 7(71):eabn5311. PMC: 9169233. DOI: 10.1126/sciimmunol.abn5311. View

12.

Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C . Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021; 9(11):1255-1265. PMC: 8360702. DOI: 10.1016/S2213-2600(21)00357-X. View

13.

Doan T, Forward T, Tamburini B . Trafficking and retention of protein antigens across systems and immune cell types. Cell Mol Life Sci. 2022; 79(5):275. PMC: 9063628. DOI: 10.1007/s00018-022-04303-4. View

14.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

15.

Hall V, Ferreira V, Wood H, Ierullo M, Majchrzak-Kita B, Manguiat K . Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat Immunol. 2022; 23(3):380-385. DOI: 10.1038/s41590-021-01126-6. View

16.

Klemis V, Schmidt T, Schub D, Mihm J, Marx S, Abu-Omar A . Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. Nat Commun. 2022; 13(1):4710. PMC: 9366133. DOI: 10.1038/s41467-022-32321-0. View

17.

Roltgen K, Nielsen S, Silva O, Younes S, Zaslavsky M, Costales C . Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. 2022; 185(6):1025-1040.e14. PMC: 8786601. DOI: 10.1016/j.cell.2022.01.018. View

18.

Schwarz T, Tober-Lau P, Hillus D, Helbig E, Lippert L, Thibeault C . Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. Emerg Infect Dis. 2021; 27(8):2174-2178. PMC: 8314803. DOI: 10.3201/eid2708.211145. View

19.

Muller L, Andree M, Moskorz W, Drexler I, Walotka L, Grothmann R . Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. Clin Infect Dis. 2021; 73(11):2065-2072. PMC: 8135422. DOI: 10.1093/cid/ciab381. View

20.

Schmidt T, Klemis V, Schub D, Schneitler S, Reichert M, Wilkens H . Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. Am J Transplant. 2021; 21(12):3990-4002. PMC: 8652989. DOI: 10.1111/ajt.16818. View